No price history available.

Based on consensus from external analysts. Not Kvantra's opinion.

Oxford BioDynamics Plc operates as a biotechnology firm that specializes in identifying and advancing biomarkers, primarily for the pharmaceutical and biotechnology sectors across global markets, including the United States. Its flagship offering is EpiSwitch, an exclusive technological platform employed for discovering, assessing, validating, and tracking epigenetic biomarkers, specifically referred to as chromosome conformation signatures. These are crucial for developing medical diagnostic kits, predicting disease onset, aiding in diagnosis, and informing therapeutic strategies. The company's key products encompass the EpiSwitch CiRT (Checkpoint Inhibitor Response Test), a validated prognostic tool for forecasting patient responses to checkpoint inhibitor immunotherapy; the EpiSwitch CST (Covid Severity Test), a sophisticated blood test designed to predict the severity of COVID-19 in adults; and the EpiSwitch Explorer Array Kit, which enables high-resolution 3D genome analysis and novel biomarker discovery. Established in 2007, Oxford BioDynamics Plc maintains its headquarters in Oxford, United Kingdom.

• RVL Pharmaceuticals plc
• MetaVia Inc.
• BioVaxys Technology Corp.
• Onconetix, Inc.
• Institute of Biomedical Research Corp.
• Creative Medical Technology Holdings, Inc.
• Aditxt, Inc.
• Dogwood Therapeutics, Inc.